FDA 警告信指出中国某药品生产厂缺少放行检测、有效期缺乏数据支持
FDA Warning Letter Highlights Analytical Deficiencies: Lack of Release Testing and Unsupported Expiry Dates
FDA 在 2025 年 3 月 24 日签发、6 月 3 日公布的警告信中,指出 2024 年 8 月检查中国一家药品生产厂时发现的分析 GMP 违规。违规包括药品批次未经活性成分鉴别与含量检测即销往美国市场,有效期所依据的稳定性数据来自与美国市场不同的国内配方,不能代表美国产品。
转述的警告信列出分析缺陷与FDA要求的多项整改,可作为检查中放行检测与稳定性数据关注点的参考。
In a Warning Letter dated 24 March 2025 and published on 03 June 2025, the U.S. Food and Drug Administration (FDA) criticizes major analytical GMP violations observed during an inspection in August 2024 at a Chinese drug manufacturing facility.Key issues include: Lack of release testing: Drug batches were distributed to the U.S. market without testing for identity and strength of active ingredients. Unsupported expiry dates: Stability data was based on domestic formulations that differed from those intended for the U.S. market. As a result, the data was not representative of U.S. products.The FDA demands: A full specification list and testing plan for all distributed batches Re-testing of retain samples still within expiry A remediated stability program, including validated, stability-indicating methods A CAPA plan addressing test method verification and long-term compliance Involvement of a qualified GMP consultant to oversee remediation effortsThe full Warning Letter, issued to Huangshi Hygienic Material Medicine Co., Ltd., is available on the FDA's website.
来源:ECA GMP News · gmp-compliance.org